Market Outlook

Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant commercial reward for some well-entrenched current therapies. Emerging agents such as AbbVie/Roche/Genentech’s Venclexta/Venclyxto, Karyopharm Therapeutics’ selinexor, Sanofi/ImmunoGen’s isatuximab, and Bluebird Bio/Celgene’s bb2121 are pursuing initial approvals for the treatment of multiple myeloma, highlighting that untapped clinical and commercial potential exists in multiple myeloma for therapies with improved efficacy, novel mechanisms of action, and positioned in patient segments that are currently underserved.

Questions Answered

  • Revlimid and Velcade are widely used for the current treatment of multiple myeloma, but how will the use of these agents change over the forecast period? What impact will generic entries of these pivotal agents have on the multiple myeloma market?
  • How has the approval of Janssen’s Darzalex and Bristol-Myers Squibb/AbbVie’s Empliciti impacted the multiple myeloma market? How important will these agents become over the forecast period?
  • What are thought-leaders’ opinions on agents in Phase III development, such as Merck & Co.’s Keytruda, Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo, Sanofi/ImmunoGen’s isatuximab, Bluebird Bio/Celgene’s bb2121, and GlaxoSmithKline’s GSK2857916? What impact will these agents have on the multiple myeloma market?
  • What are the drivers and constraints in the multiple myeloma market, and how will the market evolve over the forecast period?

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Idiopathic Pulmonary Fibrosis - Epidemiology - Mature Markets
    • Introduction
      • Key Updates
      • Prevalence of Idiopathic Pulmonary Fibrosis per 100,000 People Aged 40+ in 2020 and 2040
      • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Idiopathic Pulmonary Fibrosis over the Next Twenty Years
      • Analysis of Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the Countries Under Study in 2020 by GAP Stages
    • Epidemiology Data
    • Methods
      • Diagnosed Prevalent Cases
      • Diagnosed Incident Cases
      • Severity Stages
      • Diagnosed Prevalent Cases of IPF with Gastroesophageal Reflux Disease
      • Diagnosed Prevalent Cases of IPF with Pulmonary Hypertension
      • Diagnosed Prevalent Cases of IPF with Emphysema
      • Diagnosed Prevalent Cases of IPF with Obstructive Sleep Apnea
      • Drug-Treated Prevalent Cases
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Idiopathic Pulmonary Fibrosis
        • Studies Excluded from the Analysis of Idiopathic Pulmonary Fibrosis
      • Risk/Protective Factors
        • Risk/Protective Factors for Idiopathic Pulmonary Fibrosis
      • Bibliography

    Author(s): Devashri Mukherjee, MPH; Alison Isherwood, MSc, MRes, PhD

    Research enthusiast with a flair for academic writing, member of the DRG family since April 2015 and working from the India office.

    Started off career with a bachelor’s in Dental Surgery followed by a master’s in Public health; having primarily worked in the hospital setting as a Research Consultant prior to DRG and with 10 international publications to my credit.

    Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.


    Related Reports

    Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast

    The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed...

    View Details

    Idiopathic Pulmonary Fibrosis - Unmet Need - Detailed, Expanded Analysis: (US & EU5)

    Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further d...

    View Details

    Multiple Myeloma - Epidemiology - Emerging Markets

    DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries w...

    View Details

    Multiple Myeloma - Epidemiology - Mature Markets

    DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We re...

    View Details